Opinion|Videos|July 18, 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
The panel evaluates key patient characteristics and clinical factors influencing the decision to recommend CAR T-cell therapy as a treatment option in relapsed or refractory acute lymphoblastic leukemia.
Advertisement
Video content above is prompted by the following:
- What patient factors do you take into consideration when deciding whether a patient may be a good candidate for using CAR T-cell therapy?
- What patient characteristics and/or disease attributes would you favor treatment with Brexu-cel?
- What percentage of your patients are eligible for treatment with Brexu-cel?
Advertisement
Related to this article
Carotuximab plus apalutamide demonstrated longer median progression-free survival than apalutamide alone in an interim phase 2 analysis in mCRPC.
Mayo Clinic researchers led a multicenter study that found dividing radiation into several treatments, known as fractionated stereotactic radiosurgery, reduced the risk of cancer returning after surgery
Ruxolitinib 1.5% cream outperformed placebo vehicle in reducing lesional skin involvement in patients with epidermal or superficially sclerotic cutaneous chronic GVHD.
Lung cancer experts discuss emerging strategies after immunotherapy in advanced squamous NSCLC, including updated PRESERVE-003 data from WCLC 2026.
Most patients treated with talquetamab at a single center would not have qualified for MonumenTAL-1, yet responses were similar regardless of trial eligibility.
Epcoritamab plus R-CHOP reduced the risk of progression or death by 51% vs R-CHOP alone in newly diagnosed DLBCL.
The 19-year veteran of CU Anschutz will be the fourth director in the 41-year history of Colorado’s only NCI-designated comprehensive cancer center.
The estimated 3-year OS rate with botensilimab plus balstilimab was 48% in heavily pretreated recurrent ovarian cancer in the phase 1b C-800-01 trial.
Advertisement
Advertisement
Trending on OncLive
1
Epcoritamab Plus R-CHOP Meets PFS End Point in Newly Diagnosed DLBCL
2
Botensilimab Plus Balstilimab Yields Durable OS in Recurrent Ovarian Cancer
3
FSHR-Directed CAR T-Cell Therapy Yields Instance of Stable Disease in Recurrent Ovarian Cancer
4
‘Our Impact Will Be Broad and Transformative’: Wells Messersmith, MD, Takes the Reins at CU Anschutz Cancer Center
5